Search Results
Your search for ASCO matches 408 pages
Showing 301 - 350ASTRO 2015: A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
ASTRO 2015: Genomic Classifier Appears to Predict Metastasis in Patients With Prostate Cancer Following Prostatectomy
For men with prostate cancer who have had a prostatectomy and salvage radiation therapy, analyzing their tumor genome provides clues as to whether their cancer will metastasize, thereby enabling clinicians to better personalize treatment options, according to research presented by Den et al...
ASTRO 2015: Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer
Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...
ASTRO 2015: Androgen-Deprivation Therapy for 2 Years After Radiotherapy Improves Disease-Free Survival in Patients With Advanced Prostate Cancer
A long-term follow-up of RTOG 9202 indicated that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen-deprivation therapy after radiation therapy plus short-term androgen-deprivation therapy improved disease-free survival by 60%, compared to patients...
Postprostatectomy Radiation Therapy Yields Low Toxicity and Favorable Patient-Reported Quality of Life
A prospective study of guideline-based, postoperative, image-guided intensity-modulated radiation therapy in patients with prostate cancer found low toxicity profiles and favorable patient-reported quality of life following treatment, with researchers concluding that toxicity and health-related...
Packaging Paclitaxel in Nanoparticles May Increase Drug Efficacy in Preclinical Models
Duke University researchers found that packaging the widely used cancer drug paclitaxel into nanoparticles more than doubled the drug’s effectiveness in destroying tumors in preclinical models. Their findings were published by Bhattacharyya et al in Nature Communications. Paclitaxel has been ...
Long Telomere Length Associated With Increased Lung Cancer Risk
A large-scale genetic study of the links between telomere length and risk for five common cancers found that long telomeres are associated with an increased risk of lung adenocarcinoma. No significant associations between telomere length and other cancer types or subtypes were observed. The study,...
Risk-Appropriate Therapies Now Commonplace in Prostate Cancer Treatment
After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at the University of California, San...
Study Identifies Mechanism Fueling Growth of Pancreatic and Prostate Cancer Cells
UCLA Jonsson Cancer Center scientists have identified a new mechanism that delivers a key substance that fuels the growth of pancreatic and prostate cancer cells, a finding that offers new hope in the fight against two of the deadliest forms of the disease. Their findings were published by...
DNA Repair Kinase Identified as Key Driver of Metastasis in Prostate Cancer
Researchers at Thomas Jefferson University reported finding a single molecule that appears to be the central regulator driving metastasis in prostate cancer. The study, published by Goodwin et al in Cancer Cell, offers a target for the development of a drug that could prevent metastasis in prostate ...
Study Finds Significant Drop in New Prostate Cancer Diagnoses
A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the United States declined 28% in the year following the draft recommendation from the U.S. Preventive Services Task Force (USPSTF) against routine prostate-specific antigen (PSA)...
Chemotherapy May Be Preferred Option for Some With Advanced Prostate Cancer
In a small clinical trial, scientists at Johns Hopkins Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant. The...
Study Supports Early Intervention for Prostate Cancer Patients Who Experience Significant Emotional Distress
A study led by the University at Buffalo (UB) and Roswell Park Cancer Institute (RPCI) has identified beliefs and personality traits associated with higher levels of distress in patients with newly diagnosed prostate cancer. The findings support the value of emotional and informational support for...
Men With Asthma Less Likely to Develop Lethal Prostate Cancer
A recent analysis of a large observational study has revealed that men with a history of asthma are less likely than those without it to develop lethal prostate cancer, researchers at Johns Hopkins reported. These findings were published by Platz et al in the International Journal of Cancer....
ASCO 2015: First Effective Adjuvant Chemotherapy for High-Risk, Localized Prostate Cancer
“For the first time, improvement in overall survival was observed with tolerable adjuvant chemotherapy for localized, high-risk prostate cancer,” Howard Sandler, MD, Professor of Radiation Oncology at Cedars-Sinai Medical Center in Los Angeles, announced at a press briefing at the...
AUA 2015: Studies Evaluate Effectiveness of Active Surveillance in Prostate Cancer Patients
Active surveillance has become a viable option for many men with low-risk prostate cancer who choose not to undergo active treatment such as surgery or radiotherapy. Four studies evaluating effectiveness, trends, and other considerations for active surveillance in managing prostate cancer were...
AUA 2015: New Studies Call for Smarter Approach to Prostate Cancer Screening
Prostate cancer is one of the most common cancers in American men, yet controversy over the utilization and frequency of prostate-specific antigen (PSA) screening methods remains, due to the overdiagnosis and overtreatment of men with low-grade, less-aggressive forms of the disease. At the 110th...
Urine-Based Test Improves on PSA for Detecting Prostate Cancer
A new urine-based test improved prostate cancer detection—including detecting more aggressive forms of prostate cancer—compared to traditional models based on prostate-specific antigen (PSA) levels. The results were published by Tomlins et al in European Urology. The test, developed at ...
Androgen-Deprivation Therapy May Lead to Cognitive Impairment in Prostate Cancer Patients
Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. This side effect, when occurring with chemotherapy, is commonly referred to as “chemobrain.” Signs of cognitive impairment...
ASCO 2015: Adding Chemotherapy to Initial Therapy Improves Survival in Patients With Advanced, Hormone-Naive Prostate Cancer
The UK-led STAMPEDE trial found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone-naive). Men who received docetaxel plus standard therapy lived on...
Use of Radiotherapy After Prostate Cancer Surgery Declining, Despite Evidence of Benefit
Despite strong evidence and guidelines supporting its use, postsurgical radiation therapy for prostate cancer patients at risk of tumor recurrence is declining in the United States. The study, published by Sineshaw et al in European Urology, finds fewer than 10% of patients at risk of tumor...
Cancer Rates Significantly Increased Among Patients With Hepatitis C
Results presented on April 24 at The International Liver Congress 2015 (Abstract O058) in Vienna, Austria, show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV...
AACR 2015: New PARP Inhibitor Combination Shows Early Promise for a Wide Range of Cancer Patients
A combination of two molecularly targeted drugs, olaparib (Lynparza) and the investigational agent AZD5363, was safe and yielded responses in patients with a variety of cancer types, including breast, ovarian, and prostate cancers, regardless of BRCA1/2-mutation status, according to data from the...
AACR 2015: Subgroup of Men With Metastatic Prostate Cancer Respond to Olaparib Treatment
Men with metastatic, castration-resistant prostate cancer who had mutations in genes linked to repair of damaged DNA were significantly more likely to respond to treatment with olaparib (Lynparza) compared with patients who had the disease without these mutations. These findings from the first...
Study Examines Impact of Hospital Volume on Complication Rates in Patients Undergoing Robotic Prostate Surgery
A disincentive for hospitals that have invested in expensive technology for robotic surgery may be jeopardizing prostate cancer patients who seek out the procedure, concluded a study published by Sammon et al in BJU International. The study compared complication rates in hospitals with low...
Obesity Significantly Increases Prostate Cancer Risk in African American Men
Obesity in black men substantially increased the risk of low- and high-grade prostate cancer, whereas obesity in white men moderately reduced the risk of low-grade cancer and only slightly increased the risk of high-grade cancer, according to the first large, prospective study to examine how race...
Physical Activity Helps Cancer Survivors Fend Off Side Effects
Three or more hours of walking per week can boost the vitality and health of prostate cancer survivors. Men and women who have survived colorectal cancer and are regular walkers also reported lower sensations of burning, numbness, tingling, or loss of reflexes that many often experience after...
Asian Americans Have Better Cancer-Specific Mortality Than Non-Hispanic Whites
Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been diagnosed with cancer. In a new study published in the Journal of the National Cancer...
Younger Men Who Survive 10 Years After Radical Prostatectomy Are More Likely to Die of Non–Cancer-Related Causes
A new study suggests that after radical prostatectomy for high-risk prostate cancer, both the age of the patient and the time survived since the operation have a significant impact on the cause of death. This means that, for young men with high-risk prostate cancer, doctors may have to reevaluate...
Smokers Have Twice the Risk of Prostate Cancer Recurrence After Surgery as Never-Smokers
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research by Rieken et al presented at the European Association of Urology (EAU) 2015 Congress in Madrid (Abstract 508). In 2012,...
Breast Cancer Risk May Increase in Women Who Have First-Degree Relatives With a History of Prostate Cancer
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. Researchers from multiple institutions published their findings in a study by Beebe-Dimmer et al in Cancer. The study's results indicate that clinicians should take a...
Early Study Shows Cabazitaxel May Be More Effective Than Docetaxel in Some Patients With Advanced Prostate Cancer
In a new study reported by de Leeuw et al in Clinical Cancer Research, researchers found that the novel taxane cabazitaxel (Jevtana) has properties that could make it more effective than docetaxel in some patients with advanced prostate cancer. This hypothesis is currently being tested in a phase...
Sipuleucel-T Demonstrates Sustained Immune Response 2 Years After Treatment in Biochemically Recurrent Prostate Cancer
Preliminary results from the phase II STAND trial have demonstrated a robust immune response with sipuleucel-T (Provenge) that continues 2 years after completing treatment in men with biochemically recurrent prostate cancer. The findings, along with data from an ongoing phase IV registry related to ...
Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased Survival
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA > 10...
Men Who Have Had Testicular Cancer May Be More Likely to Develop Prostate Cancer
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among those without a history of testicular cancer (2.8%). Men who have had testicular cancer were also more likely to develop...
Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011 to 2013
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 found a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by ...
Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer. Treatment outcomes were largely similar for the 17 patients with...
ASCO Endorses American Cancer Society Prostate Cancer Survivorship Care Guidelines
The American Society of Clinical Oncology (ASCO) has issued an endorsement of the American Cancer Society's (ACS) Prostate Cancer Survivorship Care Guidelines. These guidelines provide recommendations to primary care physicians on best practices in follow-up care for men after prostate cancer...
Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer
Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than standard-of-care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...
Patients With Detectable PSA After Radical Prostatectomy May Benefit From More Aggressive Radiotherapy, 10-Year Post-Treatment Analysis Shows
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
High-Risk Prostate Cancer Detection More Likely With Targeted MRI/Ultrasound Fusion Technique Than With Standard Biopsy
Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a study by Siddiqui et al published in JAMA. More than 1,000 men participated in the research at the ...
Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
Analysis of Unexplored Part of Human Genome May Lead to Cancer Biomarker Development
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer
Adding radiation treatment to androgen-deprivation therapy saves more lives among older men with locally advanced prostate therapy than androgen-deprivation therapy alone, according to a new study reported by Bekelman et al in the Journal of Clinical Oncology. The researchers found that...
Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
ASCO Endorses AUA/ASTRO Guideline on Adjuvant and Salvage Radiotherapy After Prostatectomy
The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical...
Researchers Discover Genetic Variant That Can Predict Aggressive Prostate Cancer at Diagnosis
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...
ESMO 2014: Abiraterone Plus Prednisone Significantly Improves Overall Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...
ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer
Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...
ASTRO: Shorter Course of Androgen-Deprivation Therapy Yields Improved Quality of Life for High-Risk Prostate Cancer Patients
Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...
